Healthcare Industry News: Microbion Pharma
News Release - October 25, 2019
Microbion Corporation Announces Generic Name for Lead Antimicrobial Compound: PravibismaneFirst in a New Class of Microbial Bioenergetic Inhibitors
BOZEMAN, Mont. and VANCOUVER, British Columbia, Oct. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp. of Vancouver, BC ("Microbion") today announced that the World Health Organization (WHO) has recommended "pravibismane" as the International Nonproprietary Name (INN), also commonly known as a generic name, for Microbion's lead broad-spectrum antimicrobial and antibiofilm agent.
"The recognition of pravibismane as the first in a new class of microbial bioenergetic inhibitors is a significant distinction that we believe underscores its differentiated potential for addressing significant unmet medical needs," said Mr. Karim Lalji, Microbion's Chairman & CEO. "Pravibismane's potent, broad-spectrum activity has been demonstrated against a diverse range of multidrug-resistant priority pathogens. Pravibismane has a novel mechanism of action that uniquely demonstrates potent activity against biofilms and is effective against both susceptible and resistant Gram-positive and Gram-negative pathogens with a reduced risk of developing antibiotic resistance."
Microbion has completed Phase 1 and early Phase 2 trials of pravibismane formulated for topical and intrasurgical administration in diabetic foot ulcer infections and orthopedic device-related infections, respectively.
Microbion is a clinical-stage biopharmaceutical company that is developing pravibismane as the first product in a new class for the local treatment of antibiotic-resistant and difficult to treat infections. Pravibismane has broad spectrum, antibacterial efficacy against a broad range of pathogens, including multiple priority pathogens or "superbugs" identified by the US CDC. In addition to antibacterial efficacy, pravibismane has also demonstrated the ability to eradicate microbial biofilms. This dual antimicrobial action from this first-in-class microbial bioenergetic inhibitor provides a much-needed novel clinical approach to treat infections. Microbion has been granted QIDP and Fast Track designations for multiple indications by US FDA.
For more information visit www.microbioncorp.com.
Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.